Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00274638
Status:
COMPLETED
Last Update Posted:
2013-12-09
First Post:
2006-01-10
Brief Title:
PROBE Parallel 6-week Treatment Comparing TelmisartanHydrochlorothiazide HCT 40125 or 80125 With LosartanHCT 50125 Using Ambulatory Blood Pressure Monitoring ABPM
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Prospective Randomised Open-Label Blinded-Endpoint Parallel Group 6-week Treatment Study Comparing Telmisartan Combined With Hydrochlorothiazide 40 mg125 mg or 80 mg125 mg Tablets With Losartan Combined With Hydrochlorothiazide 50 mg125 mg Tablets Using Ambulatory Blood Pressure Monitoring in Patients With Mild-to-Moderate Hypertension
Status:
COMPLETED
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To demonstrate that Telmisartan combined with Hydrochlorothiazide MICARDIS HCT is superior to Losartan with Hydrochlorothiazide Hyzaar in lowering blood pressure in mild-moderate hypertensives
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None